Who Actually Treats You at MoldCo?

Telehealth raises a fair question: if you can't walk into a clinic, who's actually treating you, and how do you know they understand mold-related illness versus generic primary care delivered through a screen?

At MoldCo, the answer has three parts. Certified nurse practitioners who work with us full-time and see nothing but mold-related illness. Medical direction from the physician who has personally treated more patients with this condition than almost any physician on earth. And a research base established by the physician who first defined the field.

Full-time providers, not contractors

MoldCo providers are certified nurse practitioners who work with us full-time. They aren't moonlighting across multiple telehealth platforms. They aren't contractors picking up shifts. Their entire clinical focus is mold-related illness.

That matters for continuity. When a question comes in at week six about your binder dose, or at month three about whether you're ready for the next protocol phase, you're messaging a provider who already knows your case. You're not starting over with whoever picked up the next shift.

It also matters for depth. Pattern recognition comes from seeing the same illness over and over. Across MoldCo's panel, our providers have now seen hundreds of presentations of mold-related illness. They know what a binder intensification reaction looks like, which symptoms move quickly in the Clear phase, and which tend to track with ongoing environmental exposure. That's not a depth a provider splitting time across twelve conditions can build.

Our hiring bar is high on purpose. The role asks for real clinical experience, comfort with complex cases, and a temperament suited to chronic illness where progress is measured across months rather than single visits. Every provider clears that bar before they see a patient.

How providers are trained and stay current

Before any MoldCo provider sees a single patient, they complete an in-depth, month-long training program focused on mold-related illness. The curriculum covers the Shoemaker research base, the three-phase protocol (Detox, Clear, Repair), how to read inflammatory biomarkers in context (MSH, TGF-beta1, MMP-9), colesevelam titration, MARCoNS-directed nasal therapy, and if and when the final VIP phase is appropriate. Training is delivered through written materials, video instruction, and one-on-one didactic sessions with the physicians who defined this field.

Training doesn't stop after that first month. Our medical team reviews new peer-reviewed research continuously and refines our standard of care as the evidence evolves. We meet regularly as a team to review cases, compare notes, and adjust our approach based on what we're seeing across the patient population.

Clinical leadership at MoldCo

Three roles are worth knowing about.

Dr. Ritchie Shoemaker, Founding Physician. Dr. Shoemaker identified Chronic Inflammatory Response Syndrome (CIRS) as a distinct condition and developed the sequential protocol that remains the foundation of evidence-based mold illness treatment. His peer-reviewed research (double-blind placebo-controlled trials, brain-imaging work showing reversible volumetric changes with treatment, and a body of publications spanning decades) is the research base our clinical approach rests on; a recent CIRS evidence review summarizes the protocol literature and its limitations.

Dr. Scott McMahon, Medical Director. Dr. McMahon has personally treated roughly 2,000 patients with mold-related illness. To our knowledge, that's one of the largest patient panels of any physician in this specialty. As Medical Director, he leads case review, protocol oversight, and provider training. Unusual presentations, tough titrations, and patients whose symptoms aren't moving the way they should escalate to him directly.

Ally D'Amico, Director of Clinical Operations. Ally leads the operational side of the care model: scheduling, provider support, and coordination across the care team, so your provider's time stays on clinical decisions and patient relationships.

The short version: Dr. Shoemaker's research defines the what. Dr. McMahon's clinical experience defines the how. The operational team makes sure the care model runs the way it's designed to. Your provider isn't practicing in isolation.

What ongoing care actually looks like

The other misperception worth clearing up is that telehealth mold-illness care is a prescription pad with a video call bolted on. That isn't what happens at MoldCo.

Care is relationship-based and continuous. Once you're a patient, you have unlimited messaging with your care team, so questions about side effects, dose timing, or symptom flares get answered without waiting for the next scheduled visit. Your provider monitors your progress through regular symptom check-ins and, when appropriate, blood biomarker panels. The protocol gets adjusted based on what's happening in your body, not a fixed script.

Concretely, your provider decides when to titrate your colesevelam, whether and when to add EDTA nasal therapy to address suspected MARCoNS and biofilms, when to reassess labs, and whether the VIP phase is appropriate at the end of the sequence. Those decisions happen inside an ongoing care relationship, not a one-shot appointment.

Under this care model, MoldCo patients have achieved a 95% symptom-improvement rate. That number reflects what happens when continuity, clinical depth, and a defined research base all sit in the same place.

Finding out more

If you want to see whether MoldCo care fits your situation, our symptom questionnaire is the shortest path. It takes a few minutes and clarifies whether your symptom pattern lines up with mold-related illness. From there, you can start your evaluation with a provider.

Full pricing is on our pricing page, and there's a 100% refund on the initial consultation fee if we turn out not to be a fit.

You shouldn't have to guess who's on the other side of the screen.

Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.